Avelumab

Trade Name: 
Bavencio
Manufacturer/Distributor: 
EMD Serono
co-developed with Pfizer Canada
Classification: 
Antineoplastic agent
ATC Class: 
L01XC - monoclonal antibody
Status: 
active
Notice of Compliance (yyyy/mm/dd): 
2017/12/18
Date Marketed in Canada (yyyy/mm/dd): 
2017/12/18
Presentation: 
Solution for IV infusion: 20 mg/mL. DIN: 02469723
Comments: 
Bavencio has received a notice of compliance with conditions pending the results of studies to verify its clinical benefit. It is indicated for the treatment of metastatic Merkel cell carcinoma or urothelial carcinoma.